Zbyněk Bortlíček - Concepedia

Author

Zbyněk Bortlíček

Also Known As

Bohuslav Melichar, Bortlicek Zbynek, Karel Hejduk, Katerina Kubackova, Radek Lakomy, Z Bortlicek, Z Bortlíček, Z. BORTLÍČEK, Z. Bortlicek, Z. Bortlíček

193

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Masaryk University Charles University Masaryk Memorial Cancer Institute Palacký University Olomouc Thomayer University Hospital

About

Zbyněk Bortlíček is an author at Masaryk University specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	408
2	Health Sciences	1	1	42
3	Public Health	1	1	19
4	Biochemistry	1	1	14
5	Cellular Therapies	1	1	33

Zbyněk Bortlíček

Publications

Citations

H-Index

Page 1

	Year	Citations
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study Alexandr Poprach, Tomáš Pavlík, Bohuslav Melichar, Annals of Oncology UrologySkin CancerNational Registry-based StudyGenitourinary CancerMedicine	2012	112
Combined Proteomics and Transcriptomics Identifies Carboxypeptidase B1 and Nuclear Factor κB (NF-κB) Associated Proteins as Putative Biomarkers of Metastasis in Low Grade Breast Cancer Pavel Bouchal, Monika Dvořáková, Theodoros I. Roumeliotis, Molecular & Cellular Proteomics	2015	90
Comparing Clinical Characteristics and Outcomes of Young-onset and Late-onset Colorectal Cancer: An International Collaborative Study Young Soo Rho, Marine Gilabert, Archil Aladashvili, Clinical Colorectal Cancer International Collaborative StudySurgical OncologyCancer EpidemiologyGastrointestinal OncologyMedicine	2017	66
G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab Ondřej Fiala, Tomáš Büchler, Beatrice Mohelníková-Duchoňová, Tumor Biology	2015	54
Various forms of <sup>18</sup>F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica Zdeněk Řehák, Jiří Vašina, Petr Němec, Biomedical Papers	2015	46
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis Tomáš Büchler, Zbyněk Bortlíček, Alexandr Poprach, European Urology UrologyGenitourinary CancerMedicineClinical TrialsRegistry-based Analysis	2015	42
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. Martin Svatoň, Ondřej Fiala, Miloš Pešek, PubMed	2016	39
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Ondřej Fiala, Miloš Pešek, Jindřich Fínek, PubMed	2014	39
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Tumor Biology	2015	38
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients Andrea Janíková, Renata Chloupková, Vít Campr, Annals of Hematology Hematological MalignancyLymphoid NeoplasiaFirst-line TherapyCell TherapyT Cell Lymphomas	2019	33

Page 1